RETRACTED ARTICLE: The effects of coenzyme Q10 supplementation on gene expression related to insulin, lipid and inflammation in patients with polycystic ovary syndrome

Rahmani, Elham; Jamilian, Mehri; Samimi, Mansooreh; Mehrizi, Maryam Zarezade; Aghadavod, Esmat; Akbari, Elmira; Tamtaji, Omid Reza; Asemi, Zatollah

doi:10.1080/09513590.2017.1381680

Cited by 43 publications

(28 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Afterwards, the same research group carried out another RCT on 40 women with a diagnosis of PCOS, observing that a supplementation for 12 weeks with CoQ 10 (100 mg/day), beside the positive effects on lipid and glucose levels, was responsible for a downregulation of gene expression of oxidized low-density lipoprotein (LDL) receptor 1 (p < 0.001) and an upregulated gene expression of PPAR-γ (p = 0.01) in peripheral blood mononuclear cells. In addition, compared to the placebo group, CoQ 10 supplementation downregulated gene expression of interleukin-1 (IL-1) (p = 0.03), IL-8 (p = 0.001), and tumor necrosis factor-alpha (TNF-α) (p < 0.001) in peripheral blood mononuclear cells of subjects with PCOS [58]. Similar results were obtained by Izadi et al in a RCT of 85 PCO women treated with CoQ 10 and/or vitamin E or placebo.…”

Section: Insulin-resistance and Type 2 Diabetesmentioning

confidence: 99%

Coenzyme Q10: Clinical Applications in Cardiovascular Diseases

et al. 2020

View full text Add to dashboard Cite

Coenzyme Q10 (CoQ10) is a ubiquitous factor present in cell membranes and mitochondria, both in its reduced (ubiquinol) and oxidized (ubiquinone) forms. Its levels are high in organs with high metabolism such as the heart, kidneys, and liver because it acts as an energy transfer molecule but could be reduced by aging, genetic factors, drugs (e.g., statins), cardiovascular (CV) diseases, degenerative muscle disorders, and neurodegenerative diseases. As CoQ10 is endowed with significant antioxidant and anti-inflammatory features, useful to prevent free radical-induced damage and inflammatory signaling pathway activation, its depletion results in exacerbation of inflammatory processes. Therefore, exogenous CoQ10 supplementation might be useful as an adjuvant in the treatment of cardiovascular diseases such as heart failure, atrial fibrillation, and myocardial infarction and in associated risk factors such as hypertension, insulin resistance, dyslipidemias, and obesity. This review aims to summarize the current evidences on the use of CoQ10 supplementation as a therapeutic approach in cardiovascular diseases through the analysis of its clinical impact on patients’ health and quality of life. A substantial reduction of inflammatory and oxidative stress markers has been observed in several randomized clinical trials (RCTs) focused on several of the abovementioned diseases, even if more RCTs, involving a larger number of patients, will be necessary to strengthen these interesting findings.

show abstract

Section: Insulin-resistance and Type 2 Diabetesmentioning

confidence: 99%

Coenzyme Q10: Clinical Applications in Cardiovascular Diseases

et al. 2020

View full text Add to dashboard Cite

show abstract

“…[43] Furthermore, CoQ10 administration was associated with improved gene expression of inflammatory markers in patients with polycystic ovary syndrome. [26] However, 100 mg/day CoQ10 supplementation to HD patients could significantly decrease CRP levels. [10] In another study, 200 mg CoQ10 supplementation for 12 weeks did not affect any beneficial effect on inflammatory markers among obese subjects.…”

Section: Discussionmentioning

confidence: 99%

“…We used 120 mg/day CoQ10 based on the previous studies. [10252627] Randomization assignment was carried out using the computer-generated random numbers. The randomized allocation sequence, enrolling participants, and allocating them to interventions were performed by a trained nutritionist at the clinic.…”

Section: Methodsmentioning

confidence: 99%

Clinical trial of the effects of coenzyme q10 supplementation on biomarkers of inflammation and oxidative stress in diabetic hemodialysis patients

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background: The aim of the study was to determine the effects of coenzyme Q10 (CoQ10) supplementation on biomarkers of inflammation and oxidative stress among diabetic hemodialysis (HD) patients. Methods: Sixty diabetic HD patients participated in the randomized, double blind, placebo-controlled clinical trial. They were randomly assigned into two groups to intake either 60 mg CoQ10 supplements ( n = 30) or placebo ( n = 30) twice a day for 12 weeks. Results: After 12 weeks of intervention, CoQ10 supplementation significantly increased total antioxidant (TAC) (54.921 ± 26.437 vs. −126.781 ± 26.437, P < 0.001) and nitric oxide (NO) levels (4.121 ± 1.314 vs. −1.427 ± 1.314, P = 0.006) and decreased C-reactive protein (CRP) (−1.302 ± 0.583 vs. 0.345 ± 0.583, 0.042) levels compared with the placebo. We did not observe any significant effect of CoQ10 supplementation on malondialdehyde (MDA) and glutathione (GSH) levels compared with the placebo. Conclusions: Overall, our study showed that CoQ10 supplementation to diabetic HD patients for 12 weeks was associated with increased levels of TAC and NO levels and decreased level of high-sensitivity CRP (hs-CRP) levels, but did not have any beneficial effects on MDA and GSH.

show abstract

“…Furthermore, CoQ has been shown to carry out epigenetic regulation in genes involved in cell signaling, intermediary metabolism, intracellular transport, transcription control, disease mutations, protein phosphorylation, and embryo development [59]. All these effects suggest that CoQ has an essential role in the modulation of gene expression, even though the underlying mechanisms are not yet fully understood [60]. In addition, CoQ may improve endothelial dysfunction, and can possibly enhance cardiac ATP production and cardiac output by exerting a positive inotropic effect upon the myocardium [61].…”

Section: Coenzyme Q10: a Panacea?mentioning

confidence: 99%

Atherosclerosis and Coenzyme Q10

Suárez-Rivero

Pastor-Maldonado

Mata

et al. 2019

IJMS

View full text Add to dashboard Cite

Atherosclerosis is the most common cause of cardiac deaths worldwide. Classically, atherosclerosis has been explained as a simple arterial lipid deposition with concomitant loss of vascular elasticity. Eventually, this condition can lead to consequent blood flow reduction through the affected vessel. However, numerous studies have demonstrated that more factors than lipid accumulation are involved in arterial damage at the cellular level, such as inflammation, autophagy impairment, mitochondrial dysfunction, and/or free-radical overproduction. In order to consider the correction of all of these pathological changes, new approaches in atherosclerosis treatment are necessary. Ubiquinone or coenzyme Q10 is a multifunctional molecule that could theoretically revert most of the cellular alterations found in atherosclerosis, such as cholesterol biosynthesis dysregulation, impaired autophagy flux and mitochondrial dysfunction thanks to its redox and signaling properties. In this review, we will show the latest advances in the knowledge of the relationships between coenzyme Q10 and atherosclerosis. In addition, as atherosclerosis phenotype is closely related to aging, it is reasonable to believe that coenzyme Q10 supplementation could be beneficial for both conditions.

show abstract

RETRACTED ARTICLE: The effects of coenzyme Q10 supplementation on gene expression related to insulin, lipid and inflammation in patients with polycystic ovary syndrome

Cited by 43 publications

References 29 publications

Coenzyme Q10: Clinical Applications in Cardiovascular Diseases

Coenzyme Q10: Clinical Applications in Cardiovascular Diseases

Clinical trial of the effects of coenzyme q10 supplementation on biomarkers of inflammation and oxidative stress in diabetic hemodialysis patients

Atherosclerosis and Coenzyme Q10

Contact Info

Product

Resources

About